Understanding how immune cells contribute to lung injury
Official title: hHv1 channels in neutrophils and the innate immune inflammatory response
Funded at University of California-Irvine · NIH-11171714 · Data updated 2026-11-12
This research explores how certain immune cells called neutrophils cause lung damage in conditions like acute lung injury and ARDS, aiming to find new ways to protect the lungs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | August 5, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $597,782 |
| NIH project number | 5R01HL159711-10 |
| Project ID | NIH-11171714 on NIH RePORTER |
Who could benefit from this research
✓Could help
Future patients suffering from or at risk of acute lung injury or acute respiratory distress syndrome could potentially benefit from this research.
✕Less likely to help
Patients without acute lung injury or ARDS, or those whose lung damage is caused by mechanisms unrelated to hHv1, may not directly benefit from this specific approach.
What this research studies
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe conditions where fluid builds up in the lungs, often leading to high mortality. Current treatments that target later stages of inflammation haven't been very successful. This project focuses on a specific protein, hHv1, found in immune cells called neutrophils, which are known to release harmful substances that damage the lungs. By developing a unique blocker for hHv1, researchers hope to stop this inflammatory process early on. This approach could potentially prevent or reduce lung damage in patients with these serious conditions.
Why it matters
Potential benefit: If successful, this work could lead to new drug therapies that target the hHv1 protein to prevent or reduce severe lung damage in patients with acute lung injury and ARDS.
How similar studies have gone: This project builds on recent advances in creating a specific blocker for hHv1, which has shown promise in suppressing inflammation in human cells and lung damage in animal models.
Where this research is happening
-
University of California-Irvine
Irvine, United States Active
Researchers
- Principal investigator: Goldstein, Steve a N — University of California-Irvine
- Study coordinator: Goldstein, Steve a N
Related research
Other NIH-funded projects on the same topics.
-
SSRI use during pregnancy: effects on placental blood flow and inflammation
This grant studies how antidepressants (SSRIs) used during pregnancy might affect the placenta and inflammation, and whether a 5-HT2 receptor blocker could mitigate any negative effects.
-
Understanding how skin inflammation is controlled to help conditions like atopic dermatitis
A study at UC San Diego investigates how skin cells regulate inflammation to prevent prolonged skin redness and injury.
-
Estrogen and neutrophil function in lung disease among adults with CF and bronchiectasis
This grant tests how estrogen may change neutrophil behavior and lung inflammation in adults with cystic fibrosis or non-CF bronchiectasis to explain why women often have worse outcomes.
-
Targeting inflammation in age-related macular degeneration
Aims to understand how inflammation drives age-related macular degeneration in people and explore new targets to slow or stop vision loss.
-
T-Cell Signals in Neonatal Heart Regeneration
This project explores how a specific immune pathway involving CD4+ T helper 2 cells may help the neonatal heart repair itself after injury in mouse models, with potential implications for human heart healing.
-
Monocyte-derived alveolar macrophages fuel lung inflammation after ozone exposure
This study looks at how certain immune cells in the lungs called monocyte-derived alveolar macrophages respond to ozone exposure and worsen lung inflammation, especially after prior lung injury.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.